Search research articles
Contact Us
Filters
Showing results (961-970 of 1,095) with videos related to
Page
of 110
Sort By:
Nature Medicine
|
January 28, 2026
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial
Serena Porcari, Chiara Ciccarese, Vitor Heidrich, et al.
European Journal of Radiology
|
April 22, 2025
AI-supported approaches for mammography single and double reading: A controlled multireader study
Beniamino Brancato, Veronica Magni, Calogero Saieva, et al.
Scientific Reports
|
March 15, 2025
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, et al.
European Urology Open Science
|
November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Gastroenterology
|
October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology
|
August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
Eric Lawitz, Maria Buti, John M Vierling, et al.
Journal of Clinical Pathology
|
November 4, 2020
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma
Matteo Brunelli, Alessandro Tafuri, Luca Cima, et al.
American Journal of Human Genetics
|
October 6, 2020
Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and In Vivo Correction
Rebecca W Y Chan, Lee Serpas, Meng Ni, et al.
Page
of 110
Search research articles
Search
Showing results (961-970 of 1,095) with videos related to
Sort By:
Page
of 110
Nature Medicine
|
January 28, 2026
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial
Serena Porcari, Chiara Ciccarese, Vitor Heidrich, et al.
European Journal of Radiology
|
April 22, 2025
AI-supported approaches for mammography single and double reading: A controlled multireader study
Beniamino Brancato, Veronica Magni, Calogero Saieva, et al.
Scientific Reports
|
March 15, 2025
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, et al.
European Urology Open Science
|
November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Gastroenterology
|
October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology
|
August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
Eric Lawitz, Maria Buti, John M Vierling, et al.
Journal of Clinical Pathology
|
November 4, 2020
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma
Matteo Brunelli, Alessandro Tafuri, Luca Cima, et al.
American Journal of Human Genetics
|
October 6, 2020
Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and In Vivo Correction
Rebecca W Y Chan, Lee Serpas, Meng Ni, et al.
Page
of 110